Viridian’s Lumvoa approval breaks Tepezza’s TED monopoly. Inside the label, Phase 3 data, safety risks, payer hurdles and ...
Achieve’s cytisinicline CRL cited a prior facility and incomplete labeling, not clinical failure. Why this CMC rejection ...
AlzeCure licensed NeuroRestore ACD856 to QuantumCell in a deal worth over $2.2B. The real story is not proof, but Alzheimer’s ...
FDA Issues CRL to Sobi for NASP in Uncontrolled Gout, but the letter did not attack the clinical case. It attacked ...
Bright biotech illustration for Unicycive’s OLC CRL, showing nanoparticle formulation, manufacturing control strategy, FDA quality risk and CDMO execution failure. The FDA did not reject Oxylanthanum ...
Pharma business news, market intelligence, and CEO-level case studies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results